Published in Lancet Neurol on January 01, 2004
Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain (2007) 2.58
Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol (2009) 1.73
Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. Curr Protein Pept Sci (2009) 1.66
Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2005) 1.65
Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry (2007) 1.52
Inhibition of amyloid-β plaque formation by α-synuclein. Nat Med (2015) 1.52
Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases. J Neuropathol Exp Neurol (2008) 1.45
Amyloid peptide channels. J Membr Biol (2004) 1.43
Creutzfeldt-Jacob disease misdiagnosed as dementia with Lewy bodies. J Neurol (2005) 1.42
Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med (2012) 1.41
Structural and functional imaging in parkinsonian syndromes. Radiographics (2014) 1.41
Alpha-synuclein alters Notch-1 expression and neurogenesis in mouse embryonic stem cells and in the hippocampus of transgenic mice. J Neurosci (2008) 1.32
Word-finding difficulty: a clinical analysis of the progressive aphasias. Brain (2007) 1.27
Attentional deficits affect activities of daily living in dementia-associated with Parkinson's disease. J Neurol Neurosurg Psychiatry (2006) 1.27
Neuropathology of non-Alzheimer degenerative disorders. Int J Clin Exp Pathol (2009) 1.27
Prodromal clinical manifestations of neuropathologically confirmed Lewy body disease. Neurobiol Aging (2008) 1.20
Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies. Neurology (2009) 1.19
Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol (2012) 1.19
Psychotic symptoms in Parkinson's disease. From description to etiology. J Neurol (2005) 1.14
Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. Neuroimage (2010) 1.14
Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One (2014) 1.12
Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol (2013) 1.11
Update on amyloid imaging: from healthy aging to Alzheimer's disease. Curr Neurol Neurosci Rep (2009) 1.07
Association between male gender and cortical Lewy body pathology in large autopsy series. J Neurol (2010) 1.06
Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. J Neurol (2009) 1.05
Dementia and cognitive impairment: epidemiology, diagnosis, and treatment. Clin Geriatr Med (2014) 1.03
Glucocerebrosidase mutations in diffuse Lewy body disease. Parkinsonism Relat Disord (2011) 1.00
Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS. NMR Biomed (2006) 0.99
Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. Neurogenetics (2008) 0.98
The neuropathology and cerebrovascular mechanisms of dementia. J Cereb Blood Flow Metab (2016) 0.98
Correlation of clinical features with argyrophilic grains at autopsy. Alzheimer Dis Assoc Disord (2009) 0.97
(123)I-Metaiodobenzylguanidine Myocardial Scintigraphy in Lewy Body-Related Disorders: A Literature Review. J Mov Disord (2015) 0.95
Cardiac (123)I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life. Eur J Nucl Med Mol Imaging (2008) 0.94
Combined exposure to Maneb and Paraquat alters transcriptional regulation of neurogenesis-related genes in mice models of Parkinson's disease. Mol Neurodegener (2012) 0.94
Neuropathologic correlates of cognition in a population-based sample. J Alzheimers Dis (2013) 0.94
Combined kinase inhibition modulates parkin inactivation. Hum Mol Genet (2008) 0.92
Can we clinically diagnose dementia with Lewy bodies yet? Transl Neurodegener (2013) 0.92
β-Amyloid 42/40 ratio and kalirin expression in Alzheimer disease with psychosis. Neurobiol Aging (2012) 0.91
Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease. Neurotherapeutics (2014) 0.90
Recent insights into the molecular genetics of dementia. Trends Neurosci (2009) 0.90
Neuropsychiatric features of frontal lobe dysfunction in autopsy-confirmed patients with lewy bodies and "pure" Alzheimer disease. Am J Geriatr Psychiatry (2013) 0.89
Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiol Aging (2014) 0.89
Neuropsychiatric profiles in dementia. Alzheimer Dis Assoc Disord (2011) 0.89
Factors associated with drug-induced visual hallucinations in Parkinson's disease. J Neurol (2005) 0.88
Multivariate classification of patients with Alzheimer's and dementia with Lewy bodies using high-dimensional cortical thickness measurements: an MRI surface-based morphometric study. J Neurol (2012) 0.88
Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer's disease dementia. J Neurol (2014) 0.87
Hyperphosphorylated tau is elevated in Alzheimer's disease with psychosis. J Alzheimers Dis (2014) 0.87
Confronting complexity in late-onset Alzheimer disease: application of two-stage analysis approach addressing heterogeneity and epistasis. Genet Epidemiol (2008) 0.86
Clinico-pathological correlations of the most common neurodegenerative dementias. Front Neurol (2012) 0.86
Are there sensitive time periods for dementia caregivers? The occurrence of behavioral and psychological symptoms in the early stages of dementia. Int Psychogeriatr (2013) 0.86
Evidence for the involvement of apoptosis-inducing factor-mediated caspase-independent neuronal death in Alzheimer disease. Am J Pathol (2010) 0.85
Genetics Underlying Atypical Parkinsonism and Related Neurodegenerative Disorders. Int J Mol Sci (2015) 0.85
Neuropathological investigation of dementia: a guide for neurologists. J Neurol Neurosurg Psychiatry (2005) 0.85
Recent advances in biomedical applications of accelerator mass spectrometry. J Biomed Sci (2009) 0.84
Brain pathologies in extreme old age. Neurobiol Aging (2015) 0.84
Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther (2015) 0.84
Hydrogen peroxide responsive miR153 targets Nrf2/ARE cytoprotection in paraquat induced dopaminergic neurotoxicity. Toxicol Lett (2014) 0.84
Dementia with Lewy bodies. Neurol Clin (2007) 0.83
Differences in rate of functional decline across three dementia types. Alzheimers Dement (2013) 0.83
α-Synuclein inclusions in the skin of Parkinson's disease and parkinsonism. Ann Clin Transl Neurol (2014) 0.83
Why patients with Alzheimer's disease may show increased sensitivity to tropicamide eye drops: role of locus coeruleus. Psychopharmacology (Berl) (2005) 0.83
Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's disease. Eur J Nucl Med Mol Imaging (2015) 0.82
Characteristics of patients misdiagnosed with Alzheimer's disease and their medication use: an analysis of the NACC-UDS database. BMC Geriatr (2013) 0.82
Structured approach to patients with memory difficulties in family practice. Can Fam Physician (2013) 0.82
UPDATE ON DEMENTIA WITH LEWY BODIES. Curr Transl Geriatr Exp Gerontol Rep (2013) 0.81
Regulation of dopamine D₃ receptor in the striatal regions and substantia nigra in diffuse Lewy body disease. Neuroscience (2013) 0.81
α-Synuclein induces alterations in adult neurogenesis in Parkinson disease models via p53-mediated repression of Notch1. J Biol Chem (2012) 0.81
Evaluation of annexin A5 as a biomarker for Alzheimer's disease and dementia with lewy bodies. Front Aging Neurosci (2013) 0.81
Convergence of pathology in dementia with Lewy bodies and Alzheimer's disease: a role for the novel interaction of alpha-synuclein and presenilin 1 in disease. Brain (2014) 0.81
Sequence variants in eukaryotic translation initiation factor 4-gamma (eIF4G1) are associated with Lewy body dementia. Acta Neuropathol (2012) 0.81
Imaging improves diagnosis of dementia with lewy bodies. Psychiatry Investig (2009) 0.81
Neural correlates of visual hallucinations in dementia with Lewy bodies. Alzheimers Res Ther (2015) 0.81
Accumulation of α-synuclein in dementia with Lewy bodies is associated with decline in the α-synuclein-degrading enzymes kallikrein-6 and calpain-1. Acta Neuropathol Commun (2014) 0.81
Comparison of costs of care between patients with Alzheimer's disease and dementia with Lewy bodies. Alzheimers Dement (2008) 0.80
Dementia with Lewy bodies. Dialogues Clin Neurosci (2004) 0.80
Postmortem 3-D brain hemisphere cortical tau and amyloid-β pathology mapping and quantification as a validation method of neuropathology imaging. J Alzheimers Dis (2013) 0.80
Serum proteomic profiling of dementia with Lewy bodies: diagnostic potential of SELDI-TOF MS analysis. J Neural Transm (Vienna) (2007) 0.80
Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial. Alzheimers Res Ther (2015) 0.79
Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story. Hum Genomics (2009) 0.79
Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems. J Neural Transm (Vienna) (2008) 0.79
Cerebrospinal fluid biomarkers for dementia with lewy bodies. Int J Alzheimers Dis (2010) 0.79
Risk of decline in functional activities in dementia with Lewy bodies and Alzheimer disease. Alzheimer Dis Assoc Disord (2011) 0.79
C9orf72 Hexanucleotide Repeat Analysis in Cases with Pathologically Confirmed Dementia with Lewy Bodies. Neurodegener Dis (2016) 0.79
Gaucher disease and the synucleinopathies: refining the relationship. Orphanet J Rare Dis (2012) 0.79
Cognition, language, and clinical pathological features of non-Alzheimer's dementias: an overview. J Commun Disord (2010) 0.79
Biomarkers for cognitive impairment in Parkinson disease. Brain Pathol (2010) 0.78
Relationship between Dementia Severity and Behavioral and Psychological Symptoms of Dementia in Dementia with Lewy Bodies and Alzheimer's Disease Patients. Dement Geriatr Cogn Dis Extra (2015) 0.78
Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson's disease with dementia: data from the Swedish Dementia Quality Registry (SveDem). Neuropsychiatr Dis Treat (2013) 0.78
Amnestic mild cognitive impairment with low myocardial metaiodobenzylguanidine uptake. Am J Neurodegener Dis (2012) 0.78
Fluctuations in cognition and alertness vary independently in dementia with Lewy bodies. Mov Disord (2013) 0.78
On visual hallucinations and cortical networks: a trans-diagnostic review. J Neurol (2015) 0.77
Neurodegeneration-associated instability of ribosomal DNA. Biochim Biophys Acta (2014) 0.77
Clinical features of dementia with lewy bodies in 35 Chinese patients. Transl Neurodegener (2014) 0.77
The basal ganglia cholinergic neurochemistry of progressive supranuclear palsy and other neurodegenerative diseases. J Neurol Neurosurg Psychiatry (2006) 0.77
Diagnosis of dementia with Lewy bodies: diagnostic performance of combined ¹²³I-IMP brain perfusion SPECT and ¹²³I-MIBG myocardial scintigraphy. Ann Nucl Med (2013) 0.77
Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study. Alzheimers Dement (Amst) (2015) 0.77
Magnetic resonance spectroscopy in the diagnosis of dementia with Lewy bodies. Biomed Res Int (2014) 0.76
The 5 Objects Test: a novel, minimal-language, memory screening test. J Neurol (2013) 0.76
Potential Modes of Intercellular α-Synuclein Transmission. Int J Mol Sci (2017) 0.76
Lewy body dementia and Parkinson's disease with dementia. J Neurol (2008) 0.76
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron (2011) 20.15
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature (2006) 11.59
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Mild cognitive impairment. Lancet (2006) 10.21
Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke (2011) 10.11
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet (2007) 9.80
Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA (2009) 8.40
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet (2011) 6.09
Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA (2008) 6.00
Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med (2012) 5.64
Alzheimer's disease. Lancet (2011) 5.35
Genomewide association studies of stroke. N Engl J Med (2009) 5.29
Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med (2010) 5.27
Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet (2013) 5.22
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol (2007) 5.09
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet (2002) 5.05
Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement (2010) 4.85
Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet (2006) 4.80
Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron (2002) 4.77
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol (2004) 4.66
Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med (2004) 4.56
Dementia diagnosis in developing countries: a cross-cultural validation study. Lancet (2003) 4.52
Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ (2011) 4.37
Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med (2012) 4.22
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Vascular cognitive impairment. Lancet Neurol (2003) 3.73
Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet (2008) 3.66
Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatry (2010) 3.66
Depressive symptoms, vascular disease, and mild cognitive impairment: findings from the Cardiovascular Health Study. Arch Gen Psychiatry (2006) 3.61
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci (2007) 3.52
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology (2012) 3.46
Incidence and prevalence of dementia in the Cardiovascular Health Study. J Am Geriatr Soc (2004) 3.43
Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol (2004) 3.37
Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet (2010) 3.34
Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol (2007) 3.25
Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc Natl Acad Sci U S A (2011) 3.23
CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet (2004) 3.12
Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study. Am J Epidemiol (2005) 3.10
Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol (2005) 3.10
The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. Am J Psychiatry (2013) 3.06
Brain structure and obesity. Hum Brain Mapp (2010) 3.04
Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol (2006) 3.02
Risk factors for dementia in the cardiovascular health cognition study. Neuroepidemiology (2003) 2.97
Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord (2006) 2.96
Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A (2005) 2.95
Missing pieces in the Parkinson's disease puzzle. Nat Med (2010) 2.90
A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord (2008) 2.81
Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex (2005) 2.80
Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline. Proc Natl Acad Sci U S A (2005) 2.79
Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol (2009) 2.79
Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet (2007) 2.73
Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. Lancet Neurol (2007) 2.72
Mild cognitive impairment and alzheimer disease: patterns of altered cerebral blood flow at MR imaging. Radiology (2009) 2.70
3D pattern of brain atrophy in HIV/AIDS visualized using tensor-based morphometry. Neuroimage (2006) 2.69
Direct evidence for a parietal-frontal pathway subserving spatial awareness in humans. Science (2005) 2.68
Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol (2009) 2.66
Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol (2012) 2.65
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA (2009) 2.59
Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans. JAMA (2013) 2.58
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord (2002) 2.56
Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci (2007) 2.55
Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet (2008) 2.48
Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord (2006) 2.47
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov (2012) 2.44
Genome-wide association studies of cerebral white matter lesion burden: the CHARGE consortium. Ann Neurol (2011) 2.37